Professional Information

Dr. G. Vimal Kumar MBBS.,MS(Gen Surg).,FRCsed Designation : Professor

  • UG : MBBS(1982)- JIPMER, Pondicherry, India
  • PG: MS (Gen Surg) (1987)-JIPMER, Pondicherry, India
  • FRCSed (1990 )-Royal College of Surgeons of Edinburgh, U.K.
  • Publications
    • Kumar GV, Smile SR, Sibal RNPost operative peritoneal lavage  in peritonitis - a prospective analysis.  International Surgery 1989; Vol 74(1): 20-2.
    • Kumar VG, Rogers IM, Cope LH. Octreotide in the Treatment of Pancreatic Fistula - A Case Report. Gastroenterology Today 1993; Vol 3(4):85.
    • Rai R, Shekar S, Kumar V, Surendran P, Mustafa M, Srinivas CR.   Kasabach Merrit Syndrome in a case of Angiokeratoma of Fordyce.  Indian Journal of Dermatology 1999 Jan-Mar; Vol 44(1): 29-30.
    • Govindan VK, Appala Raju, Sujaya Menon.  Slide presentations at scientific meetings. Are they perfect.  Bulletin of NTTC, JIPMER 2001 March; Vol 8 (1): 7
    • Govindan VK, Balashanmugam.  Acute intestinal obstruction due to solitary jejunal diverticulum.  Indian Journal of Gastroentrology 2002 Sep-Oct; Vol 21(5):199-200
    • Thomas M, Padmini SB, Govindan VK, Appalaraju B.  Oerskovia turbata and Myroides species: Rare isolates from a case of acalculus cholecystitis.  Indian Journal of Medical Microbiology 2007 July; Vol 25(3): 297-298
    • Govindan VK.  Enhancing communication skills using an OSCE and peer review.  MEDICAL EDUCATION 2008; Vol 42: 513–543
  • Clinical Trial:
    • Double blind comparison of R Bx 2258 (1.5 mg OD0 and placebo in patients with lower urinary tract symptoms due to Benign Prostatic Hypertrophy.April  to  November 2002. Study code:  RX / MACR / 2002 / 05
    • Phase 2 double blind, placebo controlled adjuvant trial of GI -4000 (an inactivated recombinant Saccharomyces cerevisae expressing mutant ras protein) combined with a Gemcitabine Regimen vs a Gemcitabine Regimen with a placebo, in patients with post resection R0/R1 pancreatic cancer. Protocol number:  GI-4000-02
    • Phase 3, Double-Blind, Randomized, Parallel-Group, placebo-controlled Study of Intravenous (IV) Methylnaltrexone Bromide in the Treatment of Post – Operative Ileus (POI Protocol number:  MNTX 3301